Company Encyclopedia
View More
name
Eyepoint Pharmaceuticals
EYPT.US
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
4.396 T
EYPT.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking131/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-98.23%E
    • Profit Margin-485.96%E
    • Gross Margin-4813.56%E
  • Growth ScoreD
    • Revenue YoY-7.38%D
    • Net Profit YoY-98.66%E
    • Total Assets YoY-16.36%E
    • Net Assets YoY-8.48%D
  • Cash ScoreD
    • Cash Flow Margin-20.58%D
    • OCF YoY-7.38%D
  • Operating ScoreD
    • Turnover0.15D
  • Debt ScoreA
    • Gearing Ratio20.47%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    EyePoint announces positive recommendation by Data Safety Monitoring Committee for phase 3 trials for Duravyu

    Nov 19 (Reuters) - EyePoint Pharmaceuticals Inc:* EYEPOINT ANNOUNCES POSITIVE RECOMMENDATION FROM INDEPENDENT DATA SAFETY MONITORING COMMITTEE FOR PIVOTAL PHASE 3 TRIALS FOR DURAVYU™ IN WET AGE-RELATED MACULAR DEGENERATION* EYEPOINT PHARMACEUTICALS INC - TOPLINE DATA FOR LUGANO EXPECTED MID-2026 Source text: Further company coverage:

    Reuters·
    US
    EYPT
    +2.29%
    Reuters·
    US
    EYPT
    +2.29%

    EyePoint Pharmaceuticals Advances DURAVYU Phase 3 Trials for Wet AMD After Positive Safety Review

    EyePoint Pharmaceuticals announced a positive safety review from the DSMC for its Phase 3 trials of DURAVYU for wet AMD. No changes to trial protocols are needed, and no new safety signals were found. Initial dosing is complete, with 25% of patients receiving a second dose. Topline data for the LUGANO trial is expected mid-2026, followed by the LUCIA trial results.

    Reuters·
    US
    EYPT
    +2.29%
    Reuters·
    US
    EYPT
    +2.29%

    Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading 8.6% Higher - Here's What Happened

    Eyepoint Pharmaceuticals (NASDAQ:EYPT) shares rose 8.6% to $12.58, with a decline in trading volume. Analysts have given a "Moderate Buy" rating, with price targets ranging from $23 to $39. The company reported a quarterly EPS of ($0.85), missing estimates, and revenue of $0.97 million. Institutional investors have adjusted their positions, owning 99.41% of the stock. Eyepoint focuses on therapeutics for retinal diseases using Durasert E technology.

    Market Beat·
    US
    EYPT
    +2.29%
    Market Beat·
    US
    EYPT
    +2.29%

    EyePoint Pharmaceuticals Grants Stock Options to New Employees

    EyePoint Pharmaceuticals Inc. has granted non-statutory stock options to seven new employees as inducement awards. The options cover 31,000 shares at an exercise price of $11.58 per share, with a ten-year term. Vesting occurs over four years, with 25% after one year and the rest monthly over three years, contingent on continued employment. This announcement was made on November 17, 2025.

    Reuters·
    US
    EYPT
    +2.29%
    Reuters·
    US
    EYPT
    +2.29%

    Promising Outlook for EyePoint Pharmaceuticals with Duravyu’s Potential Impact on Wet AMD Treatment

    Debanjana Chatterjee from JonesTrading maintains a Buy rating on EyePoint Pharmaceuticals with a $43.00 price target, citing the promising outlook of its wet AMD therapy, Duravyu. The pivotal data expected in 2026 could significantly impact treatment, supported by the company's strategic regulatory approach and financial health. Mizuho Securities also reiterated a Buy rating with a $33.00 target.

    Tip Ranks·
    US
    EYPT
    +2.29%
    Tip Ranks·
    US
    EYPT
    +2.29%